Apelin-13: A Promising Biomarker for Age-Related Macular Degeneration?

2020 ◽  
Author(s):  
Esra Vural ◽  
Leyla Hazar ◽  
Cigdem Karakukçu ◽  
M. Erkam Arslan ◽  
M. Raşit Sirem ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Age Related ◽  
Treatment Naïve ◽  
Healthy Control ◽  
Group 2

Purpose: To investigate the value of serum apelin-13 levels in age-related macular degeneration patients. Methods: Patients with dry-type AMD, treatment-naive neovascular-type AMD and the healthy control group were included in this study. Patients diagnoses were confirmed with detailed fundus examination, optical cohorence tomography and fundus flourescein angiography findings. Central foveal thickness and subfoveal choroidal thickness were evaluated. Both serum apelin-13 and vascular endothelial growth factor (VEGF) levels were measured by competitive-enzyme-linked immunosorbent assay (ELISA) principle. Results: A total of 84 patients, including 24 patients in the dry-type AMD group (group 1), 27 patients in the neovascular-type AMD (group 2) group and 33 in the control group (group 3) were included in the study. Mean BCVA were 76±4,5, 48,4±16,3, 83,4±3,09 ETDRS letters in groups 1, 2 and 3, respectively. Values of serum VEGF were 44.11±26.14 pg/mL, 56.53±53.77 pg/mL and 61.47±41.62 pg/mL in groups 1, 2 and 3, respectively (p=0.553, p=0.286, p=0.896, respectively). Values of serum apelin-13 were 586.47±167.56 pg/mL, 622.18±324.52 pg/mL, 379. 31±171.96 pg/mL in groups 1, 2 and 3, respectively (p=0.847, p=0.04, p≤0.001, respectively). There was a negative correlation between the value of serum apelin and visual acuity and choroid thickness. Conclusion: Serum apelin-13 were higher in both dry-type AMD patients and neovascular AMD patients compared to the control group. Further studies are needed.

scholarly journals Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1491
Author(s):  
Jose Navarro-Partida ◽  
Juan Carlos Altamirano-Vallejo ◽  
Luis Abraham Aceves Franco ◽  
Jesús Gonzalez-Cortes ◽  
Sergio Hernandez-Da Mota ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Triamcinolone Acetonide ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Liposome Formulation ◽  
Age Related ◽  
Treatment Naïve ◽  
Vitreoretinal Diseases

Novel strategies have been developed to reduce or avoid intravitreal injections (IVTs) of the antiangiogenic (ranibizumab (RBZ)) and anti-inflammatory (triamcinolone acetonide (TA)) agents used to treat vitreoretinal diseases. One of the strategies includes liposomes. This study evaluated the safety and efficacy of a topical triamcinolone-loaded liposome formulation (TALF) as an adjuvant to intravitreal RBZ therapy in treatment- naïve patients with neovascular age-related macular degeneration (nAMD). Subjects were randomly assigned to the RBZ-TALF or the RBZ-pro re nata (RBZ-PRN) groups. Patients from the RBZ-TALF group were instructed to apply TALF for 12 months after a single dose of RBZ. Patients from the RBZ-PRN group received three monthly RBZ-IVTs. Retreatment with RBZ was considered in the case of nAMD reactivation. Regarding safety, non-ocular abnormalities were observed during TALF therapy. Concerning efficacy, non-significant differences were identified in terms of visual acuity or central foveal thickness when the RBZ-PRN and RBZ-TALF groups were compared. It is worth noting that the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 ± 1.4 vs. 6.1 ± 1.3 IVTs; p = 0.0004). Therefore, TALF used as an adjuvant to RBZ reduces the need for RBZ-IVT retreatment with optimal visual and anatomic results.

scholarly journals Topical Triamcinolone Acetonide-Loaded Liposomes Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age Related Macular Degeneration

2021 ◽  
Author(s):  
Jose Navarro-Partida ◽  
Juan Carlos Altamirano-Vallejo ◽  
Luis Abraham Aceves Franco ◽  
Jesús Gonzalez-Cortes ◽  
Sergio Hernandez Da Mota ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Triamcinolone Acetonide ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Age Related ◽  
Treatment Naïve ◽  
Vitreoretinal Diseases ◽  
Anatomic Results

Novel strategies have been developed to reduce or to avoid the intravitreal injections (IVTs) of the antiangiogenic (ranibizumab; RBZ) and the anti-inflammatory (triamcinolone acetonide; TA) agents used to treat vitreoretinal diseases. One of the strategies include liposomes. In this study, it was evaluated the safety and efficacy of topical triamcinolone-loaded liposomes formulation (TALF) as an adjuvant to intravitreal RBZ therapy in treatment-naive patients with neovascular age related macular degeneration (nAMD). Subjects were randomly assigned to the RBZ-TALF or the RBZ-pro re nata (RBZ-PRN) group. Patients from the RBZ-TALF group were instructed to apply TALF for a 12-month period after a single dose of RBZ. Patients from the RBZ-PRN group received three monthly RBZ-IVTs. Retreatment with RBZ was considered in case of nAMD reactivation. Related to safety, non-ocular abnormalities were observed during TALF therapy. Owing to the efficacy, non-significant differences are identified in visual acuity or central foveal thickness when the RBZ-PRN and RBZ-TALF groups are compared. Importantly the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 ± 1.4 vs 6.1 ± 1.3 IVTs; p=0004). Therefore, TALF used as an adjuvant to RBZ reduce the number of RBZ-IVTs retreatment with optimal visual and anatomic results.

scholarly journals Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Ermete Giancipoli ◽  
Antonio Pinna ◽  
Francesco Boscia ◽  
Gianluigi Zasa ◽  
Giovanni Sotgiu ◽  
...  
Keyword(s):  
Pilot Study ◽  
Treatment Group ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Anti Vegf ◽  
Age Related ◽  
Intravitreal Dexamethasone

Purpose. To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. Methods. In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. Results. Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p=0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p=0.40 and p=0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. Conclusion. In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage. This trial is registered with ACTRN12618001102268.

Serum levels of ARMS2, COL8A1, RAD51B, and VEGF and their correlations in Age-Related Macular Degeneration

2021 ◽  
Vol 18 ◽  
Author(s):  
Priya Battu ◽  
Kaushal Sharma ◽  
Manjari Rain ◽  
Ramandeep Singh ◽  
Akshay Anand
Keyword(s):  
Macular Degeneration ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Statistical Correlation ◽  
Age Related Macular Degeneration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Cross Sectional ◽  
Age Related ◽  
Study Results

Background: Many factors including genetic and environmental are responsible for the incidence of age-related macular degeneration (AMD). However, its pathogenesis has not been clearly elucidated yet. Objective: This study aimed to estimate the Age-Related Maculopathy Susceptibility 2 (ARMS2), Collagen type VIII Alpha 1 chain (COL8A1), Rad 51 paralog(RAD51B), and Vascular Endothelial Growth Factor (VEGF) protein levels in serum of AMD and control participants and to further investigate their correlation to understand AMD pathogenesis. Methods: For this cross-sectional study, 31 healthy control and 57 AMD patients were recruited from Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. A blood sample was taken and serum was isolated from it. ELISA(enzyme-linked immunosorbent assay)was used for the estimation of proteins in the serum of patients. Results: ARMS2 and COL8A1 levels were significantly elevated in the AMD group than in the control group. The highest levels of ARMS2, COL8A1, and VEGF proteins were recorded for the wet AMD sub-group. The study results endorsed significant positive correlation between these following molecules; ARMS2 and COL8A1 (r=0.933, p<0.0001), ARMS2 and RAD51B (r=0.704, p<0.0001), ARMS2 and VEGF (r=0.925, p<0.0001), COL8A1 and RAD51B (r=0.736, p<0.0001), COL8A1 and VEGF (r=0.879, p<0.0001),and RAD51B and VEGF (r=0.691, p<0.0001). Conclusion: The ARMS2 and COL8A1 levels were significantly higher and RAD51B was significantly lower in the AMD group than controls. Also, a significant statistical correlation was detected between these molecules, indicating that their interaction may be involved in the pathogenesis of AMD.

scholarly journals Comparison of Cytokine Levels in the Aqueous Humor of Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration Patients

2019 ◽  
Author(s):  
Huiying Zhou ◽  
Yinyu Zhao ◽  
Mingzhen Yuan ◽  
Youxin Chen
Keyword(s):  
Macular Degeneration ◽  
Aqueous Humor ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Age Related ◽  
Cytokine Levels ◽  
Treatment Naïve ◽  
And Control ◽  
Choroidal Vasculopathy

Abstract Background The concentrations of cytokines in the aqueous humor from neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) may vary. The study was conducted to compare various cytokine levels in the aqueous humor of eyes with PCV, nAMD and control.Methods The present case control study included 49 treatment-naïve eyes from 49 patients (PCV 24, nAMD 11, and cataract 14 eyes). Totally 34 angiogenic and inflammatory cytokines in the aqueous humor were measured by Luminex bead-based multiplex array.Results The aqueous humor levels of IL-8 and IL-12p70 in the nAMD group were significantly higher than the PCV group (p=0.031, p=0.012, respectively). The levels of IL-8, IL-18, IL-21, IL-31, LIF, SDF1-α, FGF-basic, VEGF-A, and VEGF-D in the aqueous humor were significantly higher in the nAMD group and PCV group than the control (nAMD vs control, p=0.004, 0.002, 0.005, <0.0001, <0.0001, <0.0001, 0.023, <0.0001, <0.0001, respectively, PCV vs control, p=0.031, <0.0001, <0.0001, <0.0001, <0.0001, <0.0001, 0.026, <0.0001, <0.0001, respectively). In contrast, the levels of BDNF, HGF, IP-10, MCP-1, and IL-13 in the aqueous humor were significantly lower in the nAMD group and PCV group than control (nAMD vs control, p=<0.0001, <0.0001, 0.003, <0.0001, <0.0001, respectively, PCV vs control, p=<0.0001, <0.0001, <0.0001, <0.0001, <0.0001, respectively). There were significant correlations among nAMD group, PCV group and control group in aqueous humor levels of HGF, IP-10, MCP-1, IL-13, IL-31, LIF, SDF1-α, VEGF-A, VEGF-D by multivariate logistic analysis.Conclusions Various cytokines involved in inflammation and angiogenesis including HGF, IP-10, MCP-1, IL-13, IL-31, LIF, SDF1-α, VEGF-A and VEGF-D may contribute to the pathogenesis of nAMD and PCV. Measurement of IL-8 and IL-12p70 in the aqueous humor may help to differentiate nAMD and PCV.

scholarly journals Circulating salusin-beta levels in the patients with age-related macular degeneration

2021 ◽  
Vol 5 (1) ◽  
pp. 001-004
Author(s):  
Turgut Burak ◽  
Mercan Kadir ◽  
Demir Nesrin ◽  
Ilhan Nevin ◽  
Çatak Onur
Keyword(s):  
Macular Degeneration ◽  
Study Groups ◽  
Age Related Macular Degeneration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Age Related ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
And Gender ◽  
Group 1

Purpose: To evaluate the levels of salusin-beta (β-SAL) in the serum in patients with age-related macular degeneration (ARMD). Methods: Our study was designed as a controlled comparative clinical study. The β-SAL levels in serums of age and sex-matched 20 healthy volunteers as controls (Group 1), 20 patients with dry-age related macular degeneration (d-ARMD) (Group 2) and 20 patients with wet-age related macular degeneration (w-ARMD) (Group 3) were measured with the enzyme-linked immunosorbent assay (ELISA) method. Results: In our study, it was found that age and gender didn’t show a statistically significant difference among the study groups (p > 0. 05). The mean serum β-SAL levels in Group 1, Group 2 and Group 3 were 1372,17 ± 1126.69 pg/mL; 1423,71 ± 1196.84 pg/mL and 940,57 ± 1092.05 pg/mL, respectively. Although the meanβ-SAL levels in w-ARMD seem numerically lower than both the control and d-ARMD groups, this difference among the study groups was not statistically significant (p > 0.05). Conclusion: Our study suggests that β-SAL levels in the patients with ARMD and healthy controls were not different than each other. Further studies with large numbers may reveal possible relationships between β-SAL and ARMD.

scholarly journals CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Ruta Sakiene ◽  
Alvita Vilkeviciute ◽  
Loresa Kriauciuniene ◽  
Vilma Jurate Balciuniene ◽  
Dovile Buteikiene ◽  
...  
Keyword(s):  
Gene Polymorphism ◽  
Macular Degeneration ◽  
Population Control ◽  
Polymerase Chain Reaction Method ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Age Related ◽  
Healthy Control ◽  
Population Control Group ◽  
Predominant Effect

Background. Age-related macular degeneration is the leading cause of blindness in elderly individuals where aetiology and pathophysiology of age-related macular degeneration are not absolutely clear.Purpose. To determine the frequency of the genotype of rs2108622 in patients with early and exudative age-related macular degeneration.Methods. The study enrolled 190 patients with early age-related macular degeneration, 181 patients with exudative age-related macular degeneration (eAMD), and a random sample of 210 subjects from the general population (control group). The genotyping of rs2108622 was carried out using the real-time polymerase chain reaction method.Results. The analysis of rs2108622 gene polymorphism did not reveal any differences in the distribution of C/C, C/T, and T/T genotypes between the early AMD group, the eAMD group, and the control group. TheCYP4F2(1347C>T)T/Tgenotype was more frequent in males with eAMD compared to females (10.2% versus 0.8%;p=0.0052); alsoT/Tgenotype was less frequently present in eAMD females compared to healthy control females (0.8% versus 6.2%;p=0.027).Conclusion. Rs2108622 gene polymorphism had no predominant effect on the development of early AMD and eAMD. TheT/Tgenotype was more frequent in males with eAMD compared to females and less frequently present in eAMD females compared to healthy females.

scholarly journals Assesment Of Protein Profile In Vitreus Samples Of Patients With Age-Related Macular Degeneration By Proteomic Approaches

2021 ◽  
Author(s):  
Hamza Köse ◽  
Berna Özkan ◽  
Aylin Kanlı ◽  
Gürler Akpınar ◽  
Murat Kasap ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Protein Profile ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Two Dimensional Gel Electrophoresis ◽  
Biological Regulation ◽  
Immunoglobulin Kappa ◽  
Age Related ◽  
Healthy Control ◽  
A Chain

Abstract Background: To investigate the protein content in patients with age-related macular degeneration (AMD) with the aim of revealing the pathogenesis of the disease. Methods: Two groups were formed: 13 patients as the AMD group and 11 patients as the healthy control group. Vitreous samples were taken from both groups under sterile conditions and sent to the proteomics laboratory for proteomics analysis. In this study, we evaluated the proteome of vitreous samples of AMD and control groups using two-dimensional gel electrophoresis (2DE) coupled with MALDI-TOF/TOF.Results: We detected 11 proteins differentially regulated in the vitreous of AMD patients relative to healthy controls. The only protein that was up-regulated was Apolipoprotein E. We observed that Alpha 1-acid glycoprotein (AAG), Leucine-rich alpha-2-glycoprotein (LRG-1), Alpha-2-HS-glycoprotein, Haptoglobin, Alpha-Crystalline A Chain, Alpha- Crystalline B Chain, Immunoglobulin kappa constant, Beta-crystallin B2, Beta-crystallin A3, Beta-crystallin S levels were significantly decreased in patients with AMD. Conclusion: The detected proteins are related to biological regulation, retinal protection, and regulation of inflammation and angiogenesis processes. We believe that investigating these proteins will help to reveal the pathological mechanisms of AMD.

Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study

2021 ◽  
pp. 112067212110057
Author(s):  
Pierre Gascon ◽  
Prithvi Ramtohul ◽  
Charles Delaporte ◽  
Sébastien Kerever ◽  
Danièle Denis ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Real Life ◽  
Age Related Macular Degeneration ◽  
Cumulative Number ◽  
Treat And Extend ◽  
Treatment Interval ◽  
Age Related ◽  
Treatment Naïve ◽  
The Mean

Purpose: To report the visual and anatomic outcomes in treatment-naïve neovascular age-related macular degeneration (nAMD) patients treated with aflibercept under a standardized Treat and Extend (T&E) protocol for up to 3 years of follow-up in “real-life” practice. Methods: This retrospective, observational, multicenter study included patients with treatment-naïve nAMD and at least 12 months of follow-up. T&E regimen adjustment was initiated after loading phase. At each visit best-corrected visual acuity (BCVA) and optical coherence tomography parameters were performed. Results: One hundred and thirty-six eyes of 115patients had at least 1 year of follow-up with 114 and 82 eyes completing at least 2 and 3 years of follow-up, respectively (mean follow-up duration: 2.7 ± 1.3 years). Mean age was 78.6 ± 8.6 years old and 52% were women. Mean BCVA increased from 60.6 ± 18.7 letters at diagnosis to 66.9 ± 16.2 letters at 1 year (+6.3 letters, p = 0.003) and remained stable throughout the follow-up period (63.1 ± 20.3 letters (+2.5, p = 0.1) and 64.0 ± 20.1 letters (+3.4, p = 0.27) at 2 and 3 years, respectively). The mean central retinal thickness decreased significantly from 358.2 ± 87.9 µm at baseline to 302 ± 71.7 µm at 12 months and maintained stable after 36 months of follow-up (297.1 ± 76 µm, p < 0.0001). Mean number of injections was 6.6 ± 2.2, 4.8 ± 1.9, and 5.6 ± 1.7 at 1, 2, and 3 years, respectively. Mean cumulative number of 16.4 ± 5.6 injections after 3 years. Mean treatment interval was 6.8 ± 2.5 weeks at 1 year. Eight-week and 12-week treatment interval were achieved in 59.5% and 19.1%, 65.8%, and 36.8% and 69.5% and 41.5% at 1, 2, and 3 years, respectively. Conclusions: Our study demonstrated that intravitreal injections of aflibercept initiated under a standardized T&E for patients with treatment-naïve nAMD allow for significant visual improvement at 12 months, which was maintained over a 3-year follow-up period.

Sign in / Sign up

Export Citation Format

Share Document